Compare AU
Compare JZRO vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Janus Henderson Net Zero Transition Active ETF (JZRO) and the S&P US Biotech (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
JZRO | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 83 |
Median incremental investment | $0 | $619.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,456.00 |
Average age group | N/A | > 35 |
Key Summary
JZRO | CURE | |
|---|---|---|
Strategy | JZRO.AX was created on 2022-03-09 by Janus Henderson. The fund's investment portfolio concentrates primarily on theme equity. The Fund seeks to achieve a total return after fees that exceeds the total return of the Benchmark over rolling 5 year periods. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Wheaton Precious Metals Corp (5.64 %) Cameco Corp (4.33 %) Linde PLC (4.11 %) | Natera Inc (3.33 %) Incyte Corp (2.95 %) Gilead Sciences Inc (2.81 %) |
Top 3 industries | Materials (80.11 %) Utilities (11.16 %) Energy (10.93 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Canada (41.39 %) United States (27.57 %) Australia (7.16 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.85 % | 0.45 % |
Key Summary
JZRO | CURE | |
|---|---|---|
Issuer | Janus Henderson | Global X |
Tracking index | S&P Global Natural Resources | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.85 % | 0.45 % |
Price | $28.36 | $52.00 |
Size | N/A | $36.301 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.38 % | 4.24 % |
Market | ASX | ASX |
First listed date | 29/03/2022 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
JZRO | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 83 |
Median incremental investment | $0 | $619.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,456.00 |
Average age group | N/A | > 35 |
Pros and Cons
JZRO | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
JZRO | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |